Link to article at PubMed

2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.


Salmon calcitonin, hereinafter referred to as calcitonin, is a derivative of human calcitonin utilized for the management of postmenopausal osteoporosis, Paget disease of bone, and hypercalcemia. Calcitonin is a peptide hormone consisting of 32 amino acids, primarily synthesized by the parafollicular cells (C cells) of the human thyroid gland. Extensive research has been conducted on salmon calcitonin, revealing its heightened potency compared to the human variant, thus establishing it as the preferred option in clinical application. The drug's clinical significance derives from its ability to inhibit osteoclast activity and increase renal excretion of calcium. Through these mechanisms, the resorption of bone matrix and serum calcium levels are diminished. Owing to these reasons, calcitonin proves advantageous in addressing the aforementioned conditions. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacokinetics, and monitoring recommendations of calcitonin to enhance the competence of interprofessional healthcare team members when caring for patients with postmenopausal osteoporosis, Paget disease of bone, and hypercalcemia.

PMID:30725954 | Bookshelf:NBK537269

Leave a Reply

Your email address will not be published. Required fields are marked *